NCT02752074 2025-08-24A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)Incyte CorporationPhase 3 Completed706 enrolled 17 charts